These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 27090446)

  • 1. Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.
    Pezeshkpoor B; Castoldi E; Mahler A; Hanel D; Müller J; Hamedani NS; Biswas A; Oldenburg J; Pavlova A
    J Thromb Haemost; 2016 Jul; 14(7):1353-63. PubMed ID: 27090446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel FV mutation (W1920R, FVNara) associated with serious deep vein thrombosis and more potent APC resistance relative to FVLeiden.
    Nogami K; Shinozawa K; Ogiwara K; Matsumoto T; Amano K; Fukutake K; Shima M
    Blood; 2014 Apr; 123(15):2420-8. PubMed ID: 24523236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va.
    Cramer TJ; Griffin JH; Gale AJ
    Pathophysiol Haemost Thromb; 2010; 37(1):17-23. PubMed ID: 20501981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor V and thrombotic disease: description of a janus-faced protein.
    Nicolaes GA; Dahlbäck B
    Arterioscler Thromb Vasc Biol; 2002 Apr; 22(4):530-8. PubMed ID: 11950687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations.
    Castoldi E; Brugge JM; Nicolaes GA; Girelli D; Tans G; Rosing J
    Blood; 2004 Jun; 103(11):4173-9. PubMed ID: 14976057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
    Dahlbäck B
    Semin Thromb Hemost; 1999; 25(3):273-89. PubMed ID: 10443959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APC resistance: biological basis and acquired influences.
    Castoldi E; Rosing J
    J Thromb Haemost; 2010 Mar; 8(3):445-53. PubMed ID: 20002539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional characterization of factor V-Ile359Thr: a novel mutation associated with thrombosis.
    Steen M; Norstrøm EA; Tholander AL; Bolton-Maggs PH; Mumford A; McVey JH; Tuddenham EG; Dahlbäck B
    Blood; 2004 May; 103(9):3381-7. PubMed ID: 14695241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic modulation of the FV(Leiden)/normal FV ratio and risk of venous thrombosis in factor V Leiden heterozygotes.
    Segers O; Simioni P; Tormene D; Bulato C; Gavasso S; Rosing J; Castoldi E
    J Thromb Haemost; 2012 Jan; 10(1):73-80. PubMed ID: 22044617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation.
    Brugge JM; Simioni P; Bernardi F; Tormene D; Lunghi B; Tans G; Pagnan A; Rosing J; Castoldi E
    J Thromb Haemost; 2005 Dec; 3(12):2695-702. PubMed ID: 16359508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional characterization of recombinant FV Hong Kong and FV Cambridge.
    Norstrøm E; Thorelli E; Dahlbäck B
    Blood; 2002 Jul; 100(2):524-30. PubMed ID: 12091344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The activated protein C (APC)-resistant phenotype of APC cleavage site mutants of recombinant factor V in a reconstituted plasma model.
    van der Neut Kolfschoten M; Dirven RJ; Tans G; Rosing J; Vos HL; Bertina RM
    Blood Coagul Fibrinolysis; 2002 Apr; 13(3):207-15. PubMed ID: 11943934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early days of APC resistance and FV Leiden.
    Dahlbäck B
    Hamostaseologie; 2008; 28(3):103-9. PubMed ID: 18521487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor V Leiden: a disorder of factor V anticoagulant function.
    Castoldi E; Rosing J
    Curr Opin Hematol; 2004 May; 11(3):176-81. PubMed ID: 15257017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coagulation function and mechanisms in various clinical phenotypes of patients with acquired factor V inhibitors.
    Matsumoto T; Nogami K; Shima M
    J Thromb Haemost; 2014 Sep; 12(9):1503-12. PubMed ID: 25041532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of thrombin formation by activated protein C: effect of the factor V Leiden mutation.
    Tans G; Nicolaes GA; Rosing J
    Semin Hematol; 1997 Jul; 34(3):244-55. PubMed ID: 9241709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired factor V-related anticoagulant mechanisms and deep vein thrombosis associated with A2086D and W1920R mutations.
    Shimonishi N; Ogiwara K; Yoshida J; Horie K; Nakajima Y; Furukawa S; Takeyama M; Nogami K
    Blood Adv; 2023 Jun; 7(12):2831-2842. PubMed ID: 36780344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of individual activated protein C cleavage site regions in coagulation factor V for factor Va inactivation and for factor Xa activation.
    Heeb MJ; Rehemtulla A; Moussalli M; Kojima Y; Kaufman RJ
    Eur J Biochem; 1999 Feb; 260(1):64-75. PubMed ID: 10091585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The discovery of activated protein C resistance.
    Dahlbäck B
    J Thromb Haemost; 2003 Jan; 1(1):3-9. PubMed ID: 12871530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbohydrate moieties on the procofactor factor V, but not the derived cofactor factor Va, regulate its inactivation by activated protein C.
    Silveira JR; Kalafatis M; Tracy PB
    Biochemistry; 2002 Feb; 41(5):1672-80. PubMed ID: 11814362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.